Clinical trials: Schizo-affective Disorder
Schizoaffective Disorder, Schizophrenia
Effectiveness of a Mobile Texting Intervention for People With Serious Mental Illness
Testing an mHealth mobile interventionist texting program on illness management.
- Conditions
- Schizoaffective Disorder, Schizophrenia, Bipolar Disorder, Major Depressive Disorder
- Trial name
- NCT03062267
- Testing
- Mobile Interventionist
- Where
- 2 sites in United States
- Volunteers
- 49 people
- Sponsor
- University of Washington
Schizophrenia, Schizoaffective Disorder
Effects of Antipsychotic Medications on Energy Intake and Expenditure
Aim 1: To evaluate the effect of antipsychotic treatment group on Activity Energy Expenditure. The project hypothesizes that subjects treated with olanzapine will demonstrate a greater decrease in AEE over time than subjects…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Weight Gain
- Trial name
- DLW (NCT00836251)
- Testing
- H218O and 2H2O, administered as a mixed cocktail
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Washington University School of Medicine
Schizophrenia Relapse, Schizophrenia
Feasibility and Acceptability of a Smartphone App to Assess Early Warning Signs of Psychosis Relapse
About 1 in 100 people will experience an episode of psychosis. Some people will only experience one 'psychotic episode' and about a quarter of people make a full recovery.
- Conditions
- Schizophrenia Relapse, Schizophrenia, Schizo Affective Disorder, Psychotic Disorders
- Trial name
- ExPRESS:2 (NCT03558529)
- Volunteers
- 27 people
- Sponsor
- Manchester Academic Health Science Centre
Schizophrenia or Schizoaffective Disorder
Identifying Predictors of Response to Antipsychotics Using a Treatment Algorithm
The objective of this study is to evaluate predictors of response to antipsychotic medication in subjects with schizophrenia. The investigators will evaluate psychopathology,brain MRI, genetics and neuropsychological profile.
- Trial name
- NCT01016145
- Testing
- Antipsychotics
- Where
- Brazil
- Volunteers
- 126 people
- Sponsor
- University of Sao Paulo
SCHIZOPHRENIA 1 (Disorder), Schizoaffective Disorder
Cognitive Neurocomputational Task Reliability & Clinical Applications Consortium (CNTRACS): Study 1
In Study 1, investigators will test the ability of each of the seven paradigms to differentiate between schizophrenia (SZ)/schizoaffective disorder (SZA) and matched healthy control subjects (HC) and to predict individual…
- Conditions
- SCHIZOPHRENIA 1 (Disorder), Schizoaffective Disorder, Healthy Adult Participants
- Trial name
- CNTRACS (NCT07853807)
- Testing
- Motion Perception Task, Sine Wave Speech Task, Volatility Task
- Where
- 5 sites in United States
- Volunteers
- 325 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Schizophrenia, Psychotic Disorders
Kahn Study; Investigation Of The Efficacy Of Ziprasidone Versus Olanzapine In The Management Of Recent-Onset Psychosis; A Flexible-Dose, Parallel Group, Double-Blind Study
This study intends to compare novel antipsychotics ziprasidone and olanzapine, to confirm the findings of an open study -where stable patients receiving olanzapine switched to ziprasidone- which showed maintenance of clinical…
- Trial name
- NCT00145444
- Testing
- olanzapine, ziprasidone
- Where
- 7 sites in Belgium, Netherlands
- Volunteers
- 100 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophenia Disorder, Schizoaffective Disorder
Reduction of Anticholinergic Medications Among Persons With Schizophrenia or Other Psychiatric Disorders
The goal of this study is to reduce Anticholinergic Medication (ACM) in persons with psychoses or serious mental illness, when these medications are no longer needed.
- Conditions
- Schizophenia Disorder, Schizoaffective Disorder, Bipolar Disorder, Psychiatric Disorders
- Trial name
- RAMP (NCT07043803)
- Testing
- Reduction of anticholinergic medication
- Where
- 4 sites in United States
- Volunteers
- 53 people
- Sponsor
- University of Pittsburgh
Schizophrenia; Psychosis, Schizophrenia and Related Disorders
Accelerated rTMS for Psychomotor Slowing
The goal of this clinical trial is to optimize the treatment of psychomotor slowing in patients with schizophrenia using Transcranial Magnetic Stimulation (TMS).
- Conditions
- Schizophrenia; Psychosis, Schizophrenia and Related Disorders, Schizo Affective Disorder, Brief Psychotic Disorder
- Trial name
- ATMSSlowing (NCT06134661)
- Testing
- cTBS (continuous Theta Burst Stimulation)
- Where
- Switzerland
- Volunteers
- 25 people
- Sponsor
- University of Bern
Schizophrenia, Schizoaffective Disorder
Clinical Trial of Dipyridamole in Schizophrenia
This is a 6-week, randomized, double blind, parallel groups designed, olanzapine-controlled trial of oral dipyridamole in symptomatic patients with a (DSM IV) diagnosis of schizophrenia, schizoaffective or schizophreniform…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- NCT00349973
- Testing
- Dipyridamole, Olanzapine
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Maryland, Baltimore
Tobacco Use, Tobacco Smoking
Persistence Targeted Smoking Cessation in Serious Mental Illness (SMI)
Due to the pandemic, this study was modified from a randomized clinical trial to test the feasibility, initial efficacy, and mechanisms of action of our PTSC-S intervention to a feasibility and acceptability test of our…
- Conditions
- Tobacco Use, Tobacco Smoking, Tobacco Use Cessation, Tobacco Use Disorder
- Trial name
- PTSC-S (NCT03873337)
- Testing
- Persistence Targeted Smoking Cessation in SMI (PTSC-S), Nicotine patch
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Rutgers, The State University of New Jersey
Schizophrenia
Modafinil Augmentation in Chronic Schizophrenia and Schizoaffective Disorder
This is an open label 8-week trial of modafinil up to 400 mg daily added to a stable antipsychotic regimen to evaluate the effect modafinil on cognition, sedation, and weight in patients with chronic schizophrenia.
- Trial name
- NCT00838227
- Testing
- modafinil
- Sponsor
- Manhattan Psychiatric Center
High Triglycerides, Hypercholesterolemia
Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia
This is an open-label pilot study of omega-3 fatty acids (Lovaza) for hypertriglyceridemia in subjects who have been on an atypical (second-generation) antipsychotic medication.
- Conditions
- High Triglycerides, Hypercholesterolemia, Schizophrenia, Schizoaffective Disorder
- Trial name
- NCT00833976
- Testing
- Lovaza
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Massachusetts General Hospital
Schizophrenia, Schizoaffective Disorder
Accelerated TMS in Psychosis
This study is to determine the tolerability and efficacy of an accelerated schedule of Transcranial Magnetic Stimulation for treating symptoms of psychotic disorders such as schizophrenia.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Prodromal Schizophrenia
- Trial name
- ATP (NCT05567848)
- Testing
- repetitive Transcranial Magnetic Stimulation (rTMS)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Beth Israel Deaconess Medical Center
Schizophrenia, Schizoaffective Disorder
Positive Emotions Program for Schizophrenia (PEPS)
This study evaluates the addition of a 8 session psychological program, called Positive Emotions Program for Schizophrenia (PEPS) to improve motivation and pleasure in adults with schizophrenia.
- Trial name
- PEPS-RCT (NCT02593058)
- Testing
- Positive Emotions Program for Schizophrenia, Treatment As Usual
- Where
- Switzerland
- Volunteers
- 80 people
- Sponsor
- Institut et Haute Ecole de la Santé la Source
Schizophrenia
A Study Comparing the Efficacy and Safety of Ziprasidone and Aripiprazole for the Treatment fo Schizophrenia or Schizoaffective Disorder in Hospitalized Patients
The purpose of this study is to compare the efficacy and safety of ziprasidone and aripiprazole in hospitalized patients with schizophrenia or schizoaffective disorder
- Trial name
- NCT00634348
- Testing
- Aripiprazole, Ziprasidone
- Where
- 41 sites in United States
- Volunteers
- 256 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.